Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda-Abbott Deal To Split TAP Followed Several Failed Attempts

This article was originally published in PharmAsia News

Executive Summary

The deal with Abbott Laboratories to end their TAP Pharmaceutical Products partnership leaves Takeda Pharmaceuticals with a cash trove intact to buy a bigger firm. Abbott, a U.S. firm, came around to the split after it failed to sell its diagnostic machine arm to General Electric just over a year ago. Takeda was under pressure to make the deal because two of its major drugs, Prevacid (lansoprazole) for ulcers and Actos (pioglitazone hydrochloride) for diabetes, are due to lose their patent protection soon. Takeda plans to garner increased proficiency by merging TAP's sales and development arms with Takeda's other U.S. subsidiaries. (Click here for more - a subscription may be required

You may also be interested in...

Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs

The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.

FDA Finalizes Guidance On Blood Glucose Meters With Separate Documents For OTC, Rx Devices

The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.

Hahn Praises CDRH Staff For Mitigating COVID-19 Deaths

The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts